BioGenCell

12/04/2026

את הספר הזה לא כתבתי בחדר עבודה שקט, אלא בתוך הראש, אי שם בין תמרונים במילואים.

זה ספר שמלמד ילדים על עצמאות, על יצירתיות, ועל היכולת לכתוב את הסיפור של עצמם.

למי זה מתאים? ילדות וילדים בגילי 3 עד 12 (וגם להורים שלהם).

✔️משלוחים לכל הארץ.

בנוסף, ניתן לתאם איתי שיעורים, הרצאות ושעות הקראה מרתקות סביב הספר, היזמות והערכים הטמונים בו לכל הגילאים - מבוגרים, בני נוער וילדים.

מוזמנים באהבה להיכנס לאתר, להתרשם, ולרכוש עותק לילדים או לנכדים.

14/07/2024

📢 We're proud to be featured in the latest CTech by Calcalist release, focusing on BioGenCell LTD's groundbreaking cell therapy technology for microvascular disease: https://lnkd.in/d4ph7FGN
🤝 A huge thank you to our partners, investors, and advisors for your 𝐮𝐧𝐰𝐚𝐯𝐞𝐫𝐢𝐧𝐠 support!

🙏 A special thank you of course to Marius Nacht and his great team Uri Yaron and Shoham , whose $𝟏𝟔𝐌 investment is the wind in the wings of our phase 2 trial.
And Kudos to the BioGenCell LTD team for their dedication and hard work.

From the article: “Our mission is to improve quality of life and not just extend it. The same patient after treatment can after a few months walk, function, and live without pain.” Dr. Yael Porat. This is why we do what we do, and we are fortunate to have so many wonderful people committed to this journey.

If you or someone you know suffers from Critical Limb Threatening Ischemia and is at risk of losing their limb, do not hesitate to contact us: https://lnkd.in/eBa5Dcbp

https://www.calcalistech.com/ctechnews/article/hki11xl2wa

CEO Yael Porat spoke to CTech about the Israeli biotech company’s groundbreaking cell therapy technology for the common and debilitating disease whose primary treatment today is amputation

01/02/2024

BioGenCell LTD's latest: a productive AND fun dinner at University of Maryland, Baltimore (UMB) focusing on our BGC101 Phase 2 trial for Critical Limb Ischemia. This week, another patient was enrolled in this study at University of Maryland Medical Center!
BioGenCell's Debbie Mahfud was grateful to meet Khanjan Nagarsheth and the entire incredible team. As always, we are amazed by everyone's dedication to helping no-option CLTI patients.
To learn more about our trial: https://www.biogencell.net/clinical-trials/
To join or refer patients: https://www.biogencelltrial.com/

22/01/2024

Successful four days at the NY NYSPMA conference!
We had the opportunity to meet with dedicated doctors, partners and executives focused on improving patient's quality of life and avoiding amputations.

Our discussions deeply covered our multinational Phase 2 clinical trial, focusing on Chronic Limb-Threatening Ischemia - and our groundbreaking TRACT technology, which leverages a patient's blood to regenerate microvasculature.

Interested in learning more? Join us in this journey!
https://www.biogencell.net/clinical-trials/

18/01/2024

The NY24 NYSPMA conference kicks off today! 👣 Join us at booth #114!
BioGenCell LTD is excited to showcase our multinational Phase 2 clinical trial, focusing on Chronic Limb-Threatening Ischemia. We'll be diving into our groundbreaking TRACT technology, which leverages a patient's blood to regenerate microvasculature, **showing significant potential in preventing amputations.**

Meet us at booth #114 to learn more about our innovative approach and explore potential collaborations. For detailed information, visit our website:
https://www.biogencell.net/clinical-trials/
and the NIH clinical trials page: [NCT02805023](https://lnkd.in/dzDSJqfn).

Looking forward to engaging discussions and meaningful collaborations at the conference! 🙌

Join a Journey that Brings New Hopeto No-Option Patients BioGenCell’s Phase 2 Clinical Trial for BGC 101Double blind randomized placebo controlled study to assess the feasibility of BGC101(EnEPC) in treating Critical Limb Ischemia. Clinical trial Gov identifier: NCT02805023 Previous image Next ima...

10/12/2023

📢 BioGenCell LTD proudly announces the launch of our Phase 2 Clinical Trial for BGC 101 at the University of Maryland Medical Center in the U.S. This pivotal study is a double-blind, randomized, placebo-controlled trial, aiming to assess the effectiveness of BGC101(EnEPC) in treating Critical Limb Ischemia.
In these challenging times, our commitment to advancing medical care and improving patient outcomes remains strong. Stay tuned for further updates on this trial > https://lnkd.in/epRrSa4Q
https://lnkd.in/dEdzSHAc
https://finance.yahoo.com/news/biogencell-announces-launch-biogencells-fifth-180000201.html

BioGenCell, a pioneer in personalized cell therapy solutions, is excited to announce the launch of its fifth Phase II clinical trial site in the United States at the University of Maryland Medical Center. The trial is focused on significantly reducing the need for amputation in patients with Chronic...

12/11/2023

BioGenCell is proud to announce our participation in a special event at the Tel Aviv Stock Exchange - הבורסה לניירות ערך for .
This event symbolizes the resilience of biotech and high-tech innovation in Israel during these challenging times.

BioGenCell continues its Phase 2 clinical trials in CLTI, showcasing our innovation and dedication to saving lives. To learn more about our study: https://lnkd.in/epRrSa4Q

Here's to the resilience of high-tech in Israel and to a world where health and technology continue to grow hand in hand!

06/09/2023

📢 We're proud to announce BioGenCell's Phase II clinical trial site! Following Yale University, University of California San Francisco and Johns Hopkins Medicine. Westchester Medical Center is the fourth USA site of BioGenCell's international trial targeting Chronic Limb-Threatening Ischemia (CLTI) patients.
https://lnkd.in/eHGQMmM2

👉 For participation details, visit: https://lnkd.in/epRrSa4Q

10/08/2023

We're excited to announce the launch of the first-ever BioGenCell's cell-therapy Chronic Limb-Threatening Ischemia (CLTI) clinical trial in Europe, at of Thoracic and Vascular Surgery UZG!
Do you or someone you know suffer from CLTI (also known as CLI) - Join us on this groundbreaking journey or help us spread the word!
👉 To our website https://lnkd.in/eQCBmhch

27/07/2023

We are proud to share a thought-provoking piece by our CEO Yael Porat (Hebrew) regarding an issue of profound importance - a research published in the of Diabetes and Its Complications (JDC) with the alarming revelation that many diabetes patients perceive death as a preferable outcome over amputation. This disturbing finding underscores the dire need for innovative solutions.
To learn more about BioGenCell's cell-therapy based solution and the phase 2 clinical trial currently underway*: https://lnkd.in/gquuPSR6

https://apchi.co.il/%d7%97%d7%95%d7%9c%d7%99-%d7%a1%d7%95%d7%9b%d7%a8%d7%aa-%d7%9e%d7%a2%d7%93%d7%99%d7%a4%d7%99%d7%9d-%d7%9c%d7%9e%d7%95%d7%aa-%d7%95%d7%9c%d7%90-%d7%9c%d7%90%d7%91%d7%93-%d7%a8%d7%92%d7%9c/

אפצ׳י